Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129351 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL10402942 | 0.92 | — | — | |
| SCHEMBL9227620 | 0.92 | — | — | |
| Lysine SCHEMBL136469 | 0.83 | GSR (0.95) | GSRRNPEPCPB2ARG1ARG2 | |
| Lysine SCHEMBL8201285 | 0.83 | GSR (0.95) | GSRRNPEPCPB2ARG1ARG2 | |
| Lysine SCHEMBL16683 | 0.83 | GSR (0.95) | GSRRNPEPCPB2ARG1ARG2 | |
| SCHEMBL9915164 | 0.82 | GSR (0.70) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL23608089 | 0.81 | GSR (0.91) | GSRRNPEPCPB2ARG1ARG2 | |
| Lysine SCHEMBL12496887 | 0.81 | GSR (0.91) | GSRRNPEPCPB2ARG1ARG2 | |
| Lysine SCHEMBL5062296 | 0.81 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105380745-B | Crosslinking of ocular tissue | 爱尔康公司 | 2020-05-08 | — | — | CN | claimed |
| CN-109311839-A | Methylamine derivative is used for treating cancer as lysyl oxidase inhibitor | 癌症研究协会皇家癌症医院 | 2019-02-05 | — | — | CN | claimed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| CN-105380745-B | Crosslinking of ocular tissue | 爱尔康公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3153508-B1 | NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS | KYOTO PHARMA IND (JP) | 2020-03-18 | — | — | EP | disclosed |
| CN-109833517-B | A kind of cross-linking treatment method improving biovalve elastin laminin stability | 四川大学 | 2019-11-12 | — | — | CN | disclosed |
| CN-110372795-A | LOX and LOXL2 inhibitor and its application | 吉利德生物制剂公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| CN-107982531-A | Treatment relevant with lysyloxidase sample albumen 2 (LOXL2) and diagnostic method | 吉利德科学公司 | 2018-05-04 | — | — | CN | disclosed |
| CN-107513172-A | A kind of preparation method of edible collagem membrane | 四川大学 | 2017-12-26 | — | — | CN | disclosed |
| CN-105308034-B | Phosphatidylinositol 3-kinase inhibitors | 吉利德科学公司 | 2017-10-31 | — | — | CN | disclosed |
| CN-106619603-A | Application of apigenin in preparation of drugs for preventing and treating renal fibrosis | 中国人民解放军第三军医大学第三附属医院 | 2017-05-10 | — | — | CN | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3153508-A1 | NOVEL ANTICANCER AGENT | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
| CN-106456772-A | Methods for treating cardiovascular diseases | 吉利德科学公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106170292-A | Chitosan material from carbon acid solution | 金珂生物医疗公司 | 2016-11-30 | — | — | CN | disclosed |
| CN-1098716-A | Vasopressin antagonists and oxytocin antagonists | OTSUKA CHEMICAL CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | GSR 1583/4885RNPEP 1860/4885GNAI3 994/4885 |
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | GSR 1610/4885RNPEP 1956/4885GNAI3 1320/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | GSR 1610/4885RNPEP 1956/4885GNAI3 1320/4885 |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | GSR 1583/4885RNPEP 1860/4885GNAI3 994/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | GSR 1610/4885RNPEP 1956/4885GNAI3 1320/4885 |
| US-10377730-B2 | Anticancer agent | TP53, NTPCR, NQO1 | GSR 1610/4885RNPEP 1956/4885GNAI3 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.